News & Events

Channel Medsystems Secures IDE Approval and Treats First Women in the CLARITY Pivotal Study

Emeryville, California, November 14, 2016. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the treatment of the first subjects in the US phase of its CLARITY Pivotal Study. CLARITY is a multicenter study to evaluate the safety and effectiveness of the Cerene™ Cryotherapy Device for endometrial ablation in women with heavy menstrual bleeding who are finished with childbearing.


Channel Medsystems Secures $22 Million Series C Financing Led by Third Point Ventures Company Prepares to Initiate a Pivotal Study for its Novel, Office-Based Therapy for Women with Heavy Menstrual Bleeding

San Francisco, California, August 31, 2015. Channel Medsystems today announced a $22 million Series C financing led by Third Point Ventures. Additional participants in the round included new investor Longwood Fund, joined by insiders Scientific Health Development, Aperture Venture Partners, InCube Ventures and Boston Scientific. Per the terms of this financing, Jason Hong, Ph.D., of Third Point Ventures will join the Company’s Board of Directors.


Initial Studies of Channel Medsystems’ Cryothermic Therapy Demonstrate Preliminary Safety and Tolerability; Results Presented at the 42nd AAGL Global Congress

San Francisco, California, November 18, 2013. Results from histopathology and initial tolerability studies of Channel Medsystems’ novel technology for endometrial ablation were presented at last week’s AAGL Global Congress in Washington, D.C. The findings represent a first indication of the safety and effectiveness of this device, which is intended for use in the treatment of heavy menstrual bleeding, a condition that affects one in five women in the United States.


Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.

San Francisco, California. November 11, 2013. Channel Medsystems has received investigational testing authorization from Health Canada to begin enrolling patients in the Cryoablation Feasibility Trial (CRYSTAL), a multi-site clinical trial designed to evaluate its innovative cryothermic treatment for heavy menstrual bleeding due to benign causes. The CRYSTAL study is designed to evaluate the efficacy and tolerability of Channel Medsystems’ in-office cryothermic procedure. The Company expects to enroll its first patient in November.


Channel Medsystems® Names Ric Cote as President and CEO; Secures $9.7 Million Investment

San Francisco, Calif. — (May 2, 2013)—Channel Medsystems, Inc., named Ric Cote president and chief executive officer, and issued $9.7M of Series B Preferred Stock.

“Ric is an excellent fit due to our focus on creating the first truly office-based Global Endometrial Ablations technology,” said prior CEO and co-founder Dr. Dan Burnett. “We are hoping he can replicate his success at Conceptus where he successfully built revenues of their office-based procedure to over $140 million per year.”